PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 35134385-4 2022 Metformin is a biguanide and the most commonly prescribed medication for type 2 diabetes Due to its pleiotropic properties, metformin"s potential disease-modifying effects are widely studied on different pathophysiological plyers of AD such as amyloid-beta (Abeta) production and clearance, tau phosphorylation, and neuroinflammation, in relevant in vitro and in vivo models. Metformin 0-9 amyloid beta precursor protein Homo sapiens 244-256 35286856-0 2022 Abeta-responsive metformin-based supramolecular synergistic nanodrugs for Alzheimer"s disease via enhancing microglial Abeta clearance. Metformin 17-26 amyloid beta precursor protein Homo sapiens 0-5 35286856-0 2022 Abeta-responsive metformin-based supramolecular synergistic nanodrugs for Alzheimer"s disease via enhancing microglial Abeta clearance. Metformin 17-26 amyloid beta precursor protein Homo sapiens 119-124 35286856-1 2022 Here, inspired by the concept of supramolecular inclusion complex, we successfully fabricate metformin (Met)-based supramolecular nanodrugs with the Abeta-responsive on-demand drug release for synergistic Alzheimer"s disease (AD) therapy via enhancing microglial Abeta clearance. Metformin 93-102 amyloid beta precursor protein Homo sapiens 149-154 35286856-1 2022 Here, inspired by the concept of supramolecular inclusion complex, we successfully fabricate metformin (Met)-based supramolecular nanodrugs with the Abeta-responsive on-demand drug release for synergistic Alzheimer"s disease (AD) therapy via enhancing microglial Abeta clearance. Metformin 93-102 amyloid beta precursor protein Homo sapiens 263-268 35134385-4 2022 Metformin is a biguanide and the most commonly prescribed medication for type 2 diabetes Due to its pleiotropic properties, metformin"s potential disease-modifying effects are widely studied on different pathophysiological plyers of AD such as amyloid-beta (Abeta) production and clearance, tau phosphorylation, and neuroinflammation, in relevant in vitro and in vivo models. Metformin 0-9 amyloid beta precursor protein Homo sapiens 258-263 35134385-4 2022 Metformin is a biguanide and the most commonly prescribed medication for type 2 diabetes Due to its pleiotropic properties, metformin"s potential disease-modifying effects are widely studied on different pathophysiological plyers of AD such as amyloid-beta (Abeta) production and clearance, tau phosphorylation, and neuroinflammation, in relevant in vitro and in vivo models. Metformin 124-133 amyloid beta precursor protein Homo sapiens 244-256 35134385-4 2022 Metformin is a biguanide and the most commonly prescribed medication for type 2 diabetes Due to its pleiotropic properties, metformin"s potential disease-modifying effects are widely studied on different pathophysiological plyers of AD such as amyloid-beta (Abeta) production and clearance, tau phosphorylation, and neuroinflammation, in relevant in vitro and in vivo models. Metformin 124-133 amyloid beta precursor protein Homo sapiens 258-263 27554603-6 2016 Co-treatment with metformin distinct abolished the Abeta-caused actions in hNSCs. Metformin 18-27 amyloid beta precursor protein Homo sapiens 51-56 35153733-5 2021 Previous mechanistic studies have gradually unveiled the effects of metformin on AD pathology and pathophysiology, including neuronal loss, neural dysfunction, amyloid-beta (Abeta) depositions, tau phosphorylation, chronic neuroinflammation, insulin resistance, impaired glucose metabolism and mitochondrial dysfunction. Metformin 68-77 amyloid beta precursor protein Homo sapiens 160-172 35153733-5 2021 Previous mechanistic studies have gradually unveiled the effects of metformin on AD pathology and pathophysiology, including neuronal loss, neural dysfunction, amyloid-beta (Abeta) depositions, tau phosphorylation, chronic neuroinflammation, insulin resistance, impaired glucose metabolism and mitochondrial dysfunction. Metformin 68-77 amyloid beta precursor protein Homo sapiens 174-179 31610847-9 2019 Treatment with an anti-diabetes drug, Metformin, reversed Abeta-induced metabolic defects, reduced protein aggregation and normalized lifespan of GRU102. Metformin 38-47 amyloid beta precursor protein Homo sapiens 58-63 28589443-7 2017 Metformin was also found to markedly decease Beta-secretase 1 (BACE1) protein expression and activity in cell culture models and in vivo, thereby reducing BACE1 cleavage products and the production of Abeta (beta-amyloid). Metformin 0-9 amyloid beta precursor protein Homo sapiens 201-206 27554603-8 2016 Importantly, co-treatment with metformin significantly restored fragmented mitochondria to almost normal morphology in the hNSCs with Abeta. Metformin 31-40 amyloid beta precursor protein Homo sapiens 134-139 25667085-2 2015 This study demonstrates the effect of metformin, a therapeutic biguanide administered for T2DM therapy, on beta-amyloid precursor protein (APP) metabolism in in vitro, ex vivo and in vivo models. Metformin 38-47 amyloid beta precursor protein Homo sapiens 107-137 25667085-8 2015 These effects of metformin were found to be antagonized by the addition of insulin, which reduced Abeta levels, oxidative stress, mitochondrial dysfunction and cell death. Metformin 17-26 amyloid beta precursor protein Homo sapiens 98-103 19237574-8 2009 Finally, inhibition of AMP-activated protein kinase (AMPK) by the pharmacological inhibitor Compound C largely suppresses metformin"s effect on Abeta generation and BACE1 transcription, suggesting an AMPK-dependent mechanism. Metformin 122-131 amyloid beta precursor protein Homo sapiens 144-149 19237574-9 2009 Although insulin and metformin display opposing effects on Abeta generation, in combined use, metformin enhances insulin"s effect in reducing Abeta levels. Metformin 21-30 amyloid beta precursor protein Homo sapiens 59-64 19237574-9 2009 Although insulin and metformin display opposing effects on Abeta generation, in combined use, metformin enhances insulin"s effect in reducing Abeta levels. Metformin 94-103 amyloid beta precursor protein Homo sapiens 142-147 27403417-0 2016 Metformin Alleviated Abeta-Induced Apoptosis via the Suppression of JNK MAPK Signaling Pathway in Cultured Hippocampal Neurons. Metformin 0-9 amyloid beta precursor protein Homo sapiens 21-26 27403417-3 2016 The aim of the current study is to investigate the role of metformin in Abeta-induced cytotoxicity and explore the underlying mechanisms. Metformin 59-68 amyloid beta precursor protein Homo sapiens 72-77 27403417-4 2016 First, the experimental results show that metformin salvaged the neurons exposed to Abeta in a concentration-dependent manner with MTT and LDH assay. Metformin 42-51 amyloid beta precursor protein Homo sapiens 84-89 27403417-7 2016 Metformin decreased hyperphosphorylated JNK induced by Abeta; however, the protection of metformin against Abeta was blocked when anisomycin, the activator of JNK, was added to the medium, indicating that metformin performed its protection against Abeta in a JNK-dependent way. Metformin 0-9 amyloid beta precursor protein Homo sapiens 55-60 27403417-7 2016 Metformin decreased hyperphosphorylated JNK induced by Abeta; however, the protection of metformin against Abeta was blocked when anisomycin, the activator of JNK, was added to the medium, indicating that metformin performed its protection against Abeta in a JNK-dependent way. Metformin 89-98 amyloid beta precursor protein Homo sapiens 107-112 27403417-7 2016 Metformin decreased hyperphosphorylated JNK induced by Abeta; however, the protection of metformin against Abeta was blocked when anisomycin, the activator of JNK, was added to the medium, indicating that metformin performed its protection against Abeta in a JNK-dependent way. Metformin 89-98 amyloid beta precursor protein Homo sapiens 107-112 27403417-9 2016 Taken together, our findings demonstrate that metformin may have a positive effect on Abeta-induced cytotoxicity, which provides a preclinical strategy against AD for elders with diabetes. Metformin 46-55 amyloid beta precursor protein Homo sapiens 86-91 26967226-0 2016 Metformin Facilitates Amyloid-beta Generation by beta- and gamma-Secretases via Autophagy Activation. Metformin 0-9 amyloid beta precursor protein Homo sapiens 22-34 26967226-2 2016 Contrary to suggestions that anti-diabetes drugs may have potential for treating AD, we demonstrate here that the insulin sensitizing anti-diabetes drug metformin (Glucophage ) increased the generation of amyloid-beta (Abeta), one of the major pathological hallmarks of AD, by promoting beta- and gamma-secretase-mediated cleavage of amyloid-beta protein precursor (AbetaPP) in SH-SY5Y cells. Metformin 153-162 amyloid beta precursor protein Homo sapiens 205-217 26967226-2 2016 Contrary to suggestions that anti-diabetes drugs may have potential for treating AD, we demonstrate here that the insulin sensitizing anti-diabetes drug metformin (Glucophage ) increased the generation of amyloid-beta (Abeta), one of the major pathological hallmarks of AD, by promoting beta- and gamma-secretase-mediated cleavage of amyloid-beta protein precursor (AbetaPP) in SH-SY5Y cells. Metformin 153-162 amyloid beta precursor protein Homo sapiens 334-346 26967226-2 2016 Contrary to suggestions that anti-diabetes drugs may have potential for treating AD, we demonstrate here that the insulin sensitizing anti-diabetes drug metformin (Glucophage ) increased the generation of amyloid-beta (Abeta), one of the major pathological hallmarks of AD, by promoting beta- and gamma-secretase-mediated cleavage of amyloid-beta protein precursor (AbetaPP) in SH-SY5Y cells. Metformin 164-174 amyloid beta precursor protein Homo sapiens 205-217 26967226-2 2016 Contrary to suggestions that anti-diabetes drugs may have potential for treating AD, we demonstrate here that the insulin sensitizing anti-diabetes drug metformin (Glucophage ) increased the generation of amyloid-beta (Abeta), one of the major pathological hallmarks of AD, by promoting beta- and gamma-secretase-mediated cleavage of amyloid-beta protein precursor (AbetaPP) in SH-SY5Y cells. Metformin 164-174 amyloid beta precursor protein Homo sapiens 334-346 19237574-3 2009 The present study investigates whether the widely prescribed insulin-sensitizing drug, metformin (Glucophage(R)), affects APP metabolism and Abeta generation in various cell models. Metformin 87-96 amyloid beta precursor protein Homo sapiens 141-146 19237574-4 2009 We demonstrate that metformin, at doses that lead to activation of the AMP-activated protein kinase (AMPK), significantly increases the generation of both intracellular and extracellular Abeta species. Metformin 20-29 amyloid beta precursor protein Homo sapiens 187-192 19237574-5 2009 Furthermore, the effect of metformin on Abeta generation is mediated by transcriptional up-regulation of beta-secretase (BACE1), which results in an elevated protein level and increased enzymatic activity. Metformin 27-36 amyloid beta precursor protein Homo sapiens 40-45